GT Biopharma, Inc. (GTBP) News
Follow GT Biopharma, Inc. (GTBP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
GT Biopharma regains Nasdaq $1.00 minimum bid compliance after 10-day stretch
GT Biopharma regained compliance with Nasdaq's $1.00 minimum bid price requirement after its stock closed above $1.00 for at least ten consecutive business days.Key Highlights:Original SEC Filing: GT Biopharma, Inc. [ GT
REGULATION | Sep 25, 2026, 08:16 PM UTC
M
GT Biopharma raises $7.45M via convertible preferred
GT Biopharma Inc raised $7.45M through Series M convertible preferred stock and warrants, with full ratchet protection. Insiders pledged votes to help secure approvals for the financing and share increases as GTB-5550 ad
EQUITY | Sep 21, 2026, 11:28 AM UTC
L
GT Biopharma, Inc. (NASDAQ:GTBP) Gets FDA IND for GTB-5550 in Multiple Myeloma
GT Biopharma received FDA IND clearance for GTB-5550 in multiple myeloma under an IST. Trial start depends on non-dilutive grant funding. Unaudited proforma cash is about $11M, expected to fund operations into Q3 2027.Ma
REGULATION | Sep 15, 2026, 01:21 PM UTC
L
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant fun
REGULATION | Sep 15, 2026, 01:21 PM UTC
L
GTBP - GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
GTBP - GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
NEWS | Sep 15, 2026, 01:15 PM UTC
L
GT Biopharma Raises $7.45 Million in Series M Preferred Offering With Warrants, Adds Greenshoe
GT Biopharma announced a private placement of Series M 10% Convertible Preferred Stock and warrants for $7.45 million in gross proceeds ($8.28 million stated value), featuring conversion at $6.10 and full ratchet protect
EQUITY | Sep 15, 2026, 01:04 PM UTC
H
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
GT Biopharma, Inc. (NASDAQ: GTBP ) on Tuesday secured IND clearance from the U.S. Food and Drug Administration (FDA) to evaluate its novel therapeutic candidate, GTB-5550, in treating multiple myeloma. Multiple myeloma i
LIVE | Sep 15, 2026, 12:45 PM UTC
L
GTBP: Phase I trials for TriKE therapies show early promise, with key data readouts expected soon
The TriKE platform is advancing in phase I trials for both blood cancers and solid tumors, showing promising early safety and efficacy signals. The technology's modular design enables rapid adaptation to new targets, wit
NEWS | Sep 11, 2026, 08:42 PM UTC
L
GTBP: Phase I TriKE trials show early promise, with key data expected soon and broad expansion potential
The TriKE platform is advancing in phase I trials for both blood cancers and solid tumors, showing early signs of safety and efficacy, with flexible application potential across oncology and autoimmune diseases. Key data
NEWS | Sep 11, 2026, 07:34 PM UTC
L
GT Biopharma reports second-quarter 2026 financial results
GT Biopharma (GTBP) reports its second quarter 2026 financial results, per the company earnings release.
EARNINGS | Aug 14, 2026, 12:00 PM UTC